Literature DB >> 8883491

Serum lipoproteins in children and young adults: determinants and treatment strategies.

K V Porkka1, O T Raitakari.   

Abstract

Serum lipoproteins are related to vascular atherosclerotic changes as seen in necropsy studies of child fatal accident victims; therefore, efforts have been made to reveal the determinants of lipoprotein metabolism in children and young adults. Recent data emphasize the adverse effects of obesity, insulin resistance and high fat intake on lipid profiles of children, and currently many lifestyle and dietary intervention studies are in progress. Detection of hereditary dyslipidemias in childhood is presently hampered by diagnostic problems. However, with the advent of efficient tools for genetic mapping, early diagnosis of common genetic dyslipidemias will probably be possible in the near future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883491     DOI: 10.1097/00041433-199608000-00002

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  4 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits.

Authors:  S Tonstad
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

3.  Moderate weight reduction in an outpatient obesity intervention program significantly reduces insulin resistance and risk factors for cardiovascular disease in severely obese adolescents.

Authors:  J Grulich-Henn; S Lichtenstein; F Hörster; G F Hoffmann; P P Nawroth; A Hamann
Journal:  Int J Endocrinol       Date:  2011-08-22       Impact factor: 3.257

4.  Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity.

Authors:  Paola Gauffin Cano; Arlette Santacruz; Ángela Moya; Yolanda Sanz
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.